HIV-1

ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults
ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults
Pharmaceutical Business Review
ViiV Healthcare
FDA
Cabenuva
HIV-1
Flag link:
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato
Pharmaceutical Business Review
ViiV Healthcare
FDA
HIV
Dovato
HIV-1
Flag link:
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment
Pharmaceutical Business Review
HIV
NIH
ViiV Healthcare
HIV-1
drug discovery
Flag link:
ViiV Submits NDA for Once-Per-Month HIV Injectable
ViiV Submits NDA for Once-Per-Month HIV Injectable
BioSpace
ViiV Healthcare
FDA
HIV
HIV-1
cabotegravir
rilpivirine
Flag link:
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Pharmaceutical Business Review
Gilead Sciences
Biktarvy
HIV-1
HIV
Flag link:
ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment
ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment
Yahoo
ViiV Healthcare
HIV
Dolutegravir
HIV-1
lamivudine
Flag link:
Gilead's HIV-1 Drug Wins Approval in Europe
Gilead's HIV-1 Drug Wins Approval in Europe
Motley Fool
HIV-1
Gilead Sciences
Vitekta
Europe
Flag link:
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
Yahoo
Dolutegravir
ViiV Healthcare
Darunavir
HIV-1
ING114915
Flag link: